Fanin M, Fulizio L, Nascimbeni A C, Spinazzi M, Piluso G, Ventriglia V M, Ruzza G, Siciliano G, Trevisan C P, Politano L, Nigro V, Angelini C
Department of Neurosciences, University of Padova, Italy.
Hum Mutat. 2004 Jul;24(1):52-62. doi: 10.1002/humu.20058.
Limb girdle muscular dystrophy (LGMD) type 2A (LGMD2A) is caused by mutations in the CAPN3 gene encoding for calpain-3, a muscle specific protease. While a large number of CAPN3 gene mutations have already been described in calpainopathy patients, the diagnosis has recently shifted from molecular genetics towards biochemical assay of defective protein. However, an estimate of sensitivity and specificity of protein analysis remains to be established. Thus, we first correlated protein and molecular data in our large LGMD2A patient population. By a preliminary immunoblot screening for calpain-3 protein of 548 unclassified patients with various phenotypes (LGMD, myopathy, or elevated levels of serum creatine kinase [hyperCKemia]), we selected 208 cases for CAPN3 gene mutation analysis: 69 had protein deficiency and 139 had normal expression. Mutation search was conducted using SSCP, denaturing high performance liquid chromatography (DHPLC), amplification refractory mutation system (ARMS-PCR), and direct sequencing methods. We identified 58 LGMD2A mutant patients: 46 (80%) had a variable degree of protein deficiency and 12 (20%) had normal amount of calpain-3. We calculated that the probability of having LGMD2A is very high (84%) when patients show a complete calpain-3 deficiency and progressively decreases with the amount of protein; this new data offers an important tool for genetic counseling when only protein data are available. A total of 37 different CAPN3 gene mutations were detected, 10 of which are novel. In our population, 87% of mutant alleles were concentrated in seven exons (exons 1, 4, 5, 8, 10, 11, and 21) and 61% correspond to only eight mutations, indicating the regions where future molecular analysis could be restricted. This study reports the largest collection of LGMD2A patients so far in which both protein and gene mutations were obtained to draw genotype-protein-phenotype correlations and provide insights into a critical protein domain.
2A型肢带型肌营养不良症(LGMD2A)由编码钙蛋白酶-3(一种肌肉特异性蛋白酶)的CAPN3基因突变引起。虽然在钙蛋白酶病患者中已经描述了大量的CAPN3基因突变,但最近诊断已从分子遗传学转向缺陷蛋白的生化检测。然而,蛋白质分析的敏感性和特异性估计仍有待确定。因此,我们首先在大量LGMD2A患者群体中关联了蛋白质和分子数据。通过对548例具有各种表型(LGMD、肌病或血清肌酸激酶水平升高[高肌酸激酶血症])的未分类患者进行钙蛋白酶-3蛋白的初步免疫印迹筛查,我们选择了208例进行CAPN3基因突变分析:69例蛋白缺乏,139例表达正常。使用单链构象多态性(SSCP)、变性高效液相色谱(DHPLC)、扩增阻滞突变系统(ARMS-PCR)和直接测序方法进行突变搜索。我们鉴定出58例LGMD2A突变患者:46例(80%)有不同程度的蛋白缺乏,12例(20%)钙蛋白酶-3量正常。我们计算出,当患者表现出完全的钙蛋白酶-3缺乏时,患LGMD2A的概率非常高(84%),并随着蛋白量的增加而逐渐降低;当只有蛋白质数据可用时,这一新数据为遗传咨询提供了一个重要工具。共检测到37种不同的CAPN3基因突变,其中10种是新的。在我们的群体中,87%的突变等位基因集中在7个外显子(外显子1、4、5、8、10、11和21),61%仅对应于8种突变,表明未来分子分析可局限的区域。本研究报告了迄今为止最大的LGMD2A患者群体,其中同时获得了蛋白质和基因突变情况,以建立基因型-蛋白质-表型相关性,并深入了解关键蛋白结构域。